Compare Stocks: PVLA, CYTK, PRAX, and TGTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$65.53 -3.0%	$75.93	$47.22 ▼ $88.31	$8.15B	0.36	2.13 million shs	1.08 million shs
PRAX Praxis Precision Medicines	$285.66 -5.0%	$338.35	$46.99 ▼ $392.70	$7.96B	2.76	460,936 shs	788,006 shs
PVLA Palvella Therapeutics	$150.45 -4.9%	$149.75	$56.54 ▼ $161.38	$2.17B	-0.25	263,115 shs	112,542 shs
TGTX TG Therapeutics	$55.92 -3.8%	$53.53	$26.76 ▼ $59.30	$8.55B	1.67	2.18 million shs	1.31 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-2.48%	-12.04%	-16.76%	+40.08%
PRAX Praxis Precision Medicines	+0.60%	-3.91%	-20.01%	-2.68%	+522.08%
PVLA Palvella Therapeutics	+3.08%	+4.57%	+11.33%	+21.79%	+169.34%
TGTX TG Therapeutics	+1.66%	+9.56%	+7.08%	+8.41%	+66.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$65.53 -3.0%	$75.93	$47.22 ▼ $88.31	$8.15B	0.36	2.13 million shs	1.08 million shs
PRAX Praxis Precision Medicines	$285.66 -5.0%	$338.35	$46.99 ▼ $392.70	$7.96B	2.76	460,936 shs	788,006 shs
PVLA Palvella Therapeutics	$150.45 -4.9%	$149.75	$56.54 ▼ $161.38	$2.17B	-0.25	263,115 shs	112,542 shs
TGTX TG Therapeutics	$55.92 -3.8%	$53.53	$26.76 ▼ $59.30	$8.55B	1.67	2.18 million shs	1.31 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-2.48%	-12.04%	-16.76%	+40.08%
PRAX Praxis Precision Medicines	+0.60%	-3.91%	-20.01%	-2.68%	+522.08%
PVLA Palvella Therapeutics	+3.08%	+4.57%	+11.33%	+21.79%	+169.34%
TGTX TG Therapeutics	+1.66%	+9.56%	+7.08%	+8.41%	+66.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.85	Moderate Buy	$103.37	57.73% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$612.42	114.39% Upside
PVLA Palvella Therapeutics	2.93	Moderate Buy	$209.14	39.01% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	12.66% Upside

Current Analyst Ratings Breakdown

Latest PVLA, CYTK, PRAX, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
9/21/2026	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$240.00
9/11/2026	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/7/2026	TGTX TG Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/1/2026	CYTK Cytokinetics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight ➝ Buy
9/1/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00
8/31/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$140.00
8/24/2026	PRAX Praxis Precision Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00
8/14/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$88.04M	92.62	N/A	N/A	($5.39) per share	-12.16
PRAX Praxis Precision Medicines	$8.55M	932.81	N/A	N/A	$34.85 per share	8.20
PVLA Palvella Therapeutics	$42.81M	50.64	N/A	N/A	$2.36 per share	63.75
TGTX TG Therapeutics	$616.29M	13.89	$2.74 per share	20.40	$4.08 per share	13.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)
PVLA Palvella Therapeutics	-$41.72M	-$4.83	N/A	N/A	N/A	N/A	-47.84%	-38.33%	11/10/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	20.38	21.10	2.45	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest PVLA, CYTK, PRAX, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/4/2026	Q2 2026	PVLA Palvella Therapeutics	-$1.17	-$1.52	-$0.35	-$1.52	N/A	N/A
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	6.66	6.66
PRAX Praxis Precision Medicines	N/A	15.73	15.73
PVLA Palvella Therapeutics	N/A	21.18	21.18
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
PRAX Praxis Precision Medicines	67.84%
PVLA Palvella Therapeutics	40.11%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.60%
PRAX Praxis Precision Medicines	3.00%
PVLA Palvella Therapeutics	17.20%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable
PVLA Palvella Therapeutics	29	14.41 million	11.93 million	N/A
TGTX TG Therapeutics	399	153.07 million	139.49 million	Optionable

PVLA, CYTK, PRAX, and TGTX Headlines

Recent News About These Companies

Dow Jones futures fall after Nasdaq hits new high; SanDisk, Micron trigger buy signals

September 23 at 8:17 AM | msn.com

Dow Jones futures: Nasdaq hits new high; SanDisk, Micron trigger buy signals

September 22 at 5:15 PM | msn.com

Bank of America Corp DE Acquires Shares of 1,309,788 TG Therapeutics, Inc. $TGTX

September 20 at 3:04 AM | marketbeat.com

Tidal Investments LLC Buys New Holdings in TG Therapeutics, Inc. $TGTX

September 19, 2026 | marketbeat.com

TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound

September 18, 2026 | finance.yahoo.com

TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share

September 18, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Trading 8.3% Higher - Here's Why

September 16, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Director Laurence Charney Sells 5,000 Shares

September 15, 2026 | americanbankingnews.com

TG Therapeutics (NASDAQ:TGTX) Director Sells 5,000 Shares

September 15, 2026 | insidertrades.com

TG Therapeutics, Inc. $TGTX Shares Sold by WINTON GROUP Ltd

September 15, 2026 | marketbeat.com

California State Teachers Retirement System Has $9.37 Million Stock Position in TG Therapeutics, Inc. $TGTX

September 15, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Director Sells $274,800.00 in Stock

September 14, 2026 | marketbeat.com

Hsbc Holdings PLC Has $884,000 Holdings in TG Therapeutics, Inc. $TGTX

September 14, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.17 Million in TG Therapeutics, Inc. $TGTX

September 11, 2026 | marketbeat.com

TG Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026 | quiverquant.comQ

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026 | globenewswire.com

TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Strong Sell" at Zacks Research

September 9, 2026 | marketbeat.com

Wellington Management Group LLP Increases Stock Position in TG Therapeutics, Inc. $TGTX

September 6, 2026 | marketbeat.com

AXQ Capital LP Takes Position in TG Therapeutics, Inc. $TGTX

September 6, 2026 | marketbeat.com

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

September 3, 2026 | globenewswire.com

Corient Private Wealth LP Purchases Shares of 39,081 TG Therapeutics, Inc. $TGTX

September 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, CYTK, PRAX, and TGTX Company Descriptions

Cytokinetics NASDAQ:CYTK

$65.53 -2.06 (-3.04%)

As of 03:19 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Praxis Precision Medicines NASDAQ:PRAX

$285.66 -14.99 (-4.99%)

As of 03:19 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Palvella Therapeutics NASDAQ:PVLA

$150.45 -7.68 (-4.86%)

As of 03:19 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

TG Therapeutics NASDAQ:TGTX

$55.92 -2.19 (-3.77%)

As of 03:19 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PVLA, CYTK, PRAX, and TGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PVLA, CYTK, PRAX, and TGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PVLA, CYTK, PRAX, and TGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, CYTK, PRAX, and TGTX Company Descriptions

Cytokinetics NASDAQ:CYTK

Praxis Precision Medicines NASDAQ:PRAX

Palvella Therapeutics NASDAQ:PVLA

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PVLA, CYTK, PRAX, and TGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PVLA, CYTK, PRAX, and TGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PVLA, CYTK, PRAX, and TGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, CYTK, PRAX, and TGTX Company Descriptions

Cytokinetics NASDAQ:CYTK

Praxis Precision Medicines NASDAQ:PRAX

Palvella Therapeutics NASDAQ:PVLA

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools